Skip to content
Companies

Odyssey Therapeutics

Transcription factor drugs for autoimmune disease

Raised to date

$214M

of $214M offered across 1 Form D filing

Investors
55
Last filed
Dec 4, 2025

About

Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company's strategy involves targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation before it starts, aiming to induce long-lasting remission for patients.

The company differentiates itself by focusing on upstream mechanisms of the innate immune system to preemptively halt inflammation, rather than treating its downstream effects.

Funding

  • EquityFiled Dec 4, 2025Form D
    $214M/ $214M

Product

Transcription Factor Therapies Program

Small Molecule Therapies

In a strategic collaboration with Terray Therapeutics, Odyssey is co-developing first-in-class transcription factor therapies. This program combines Odyssey's expertise in immunology and transcription factor biology with Terray's AI-powered drug discovery platform, tNova, to discover and develop small molecule medicines.

  • Joint development with Terray Therapeutics
  • Utilizes AI-powered drug discovery platform (tNova)
  • Targets historically challenging transcription factor targets

Built for

Patients with autoimmune and inflammatory diseases.

People on file